Trials / Completed
CompletedNCT00544050
Pharmacokinetic Study of Levetiracetam in Epileptic Pediatric Subjects Ranging in Age From 1 Month to Less Than 4 Years Old
An Open-Label, Single Dose, Pharmacokinetic Study of 20 mg/kg of Levetiracetam Oral Solution in Epileptic Pediatric Subjects Ranging in Age From 1 Month to Less Than 4 Years Old
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 13 (actual)
- Sponsor
- UCB Pharma · Industry
- Sex
- All
- Age
- 1 Month – 4 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of this study was to document the pharmacokinetic parameters of both levetiracetam and its metabolite, ucb L057, after a single dose of 20 mg/kg of levetiracetam in epileptic pediatric subjects, aged 1 month to less than 4 years.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Levetiracetam |
Timeline
- Start date
- 2002-09-01
- Primary completion
- 2003-05-01
- Completion
- 2003-05-01
- First posted
- 2007-10-16
- Last updated
- 2013-11-15
Source: ClinicalTrials.gov record NCT00544050. Inclusion in this directory is not an endorsement.